Nitazoxanide in Patients With Metastatic Colorectal Cancer - Trial NCT06049901
Access comprehensive clinical trial information for NCT06049901 through Pure Global AI's free database. This Phase 3 trial is sponsored by Tanta University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tanta University
Timeline & Enrollment
Phase 3
Mar 01, 2023
Mar 01, 2026
Primary Outcome
Investigating the possible efficacy of nitazoxanide through evaluation of its impact on overall response rate (ORR) and disease control rate (DCR).,Evaluating the change in the serum level of Reduced glutathione (GSH),Evaluating the change in the serum level of Superoxide dismutase (SOD),Evaluating the change in the serum level of Nuclear factor-kappa B (NF-kB),Evaluating the change in the serum level of Protein disulfide isomerase (PDI)
Summary
The aim of this study is to evaluate the potential efficacy and safety of nitazoxanide in
 patients with metastatic colorectal cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06049901
Non-Device Trial